Zidovudine
Active ingredient: Zidovudine
In short: Zidovudine tablets, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Zidovudine tablets are indicated for the prevention of maternal-fetal HIV-1 transmission .
What is Zidovudine used for?
Zidovudine tablets, a nucleoside reverse transcriptase inhibitor, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Zidovudine tablets are indicated for the prevention of maternal-fetal HIV-1 transmission
.
The indication is based on a dosing regimen that included 3 components:
1. antepartum therapy of HIV-1-infected mothers
2. intrapartum therapy of HIV-1-infected mothers
3. post-partum therapy of HIV-1-exposed neonate
Points to consider prior to initiating zidovudine in pregnant women for the prevention of maternal-fetal HIV-1 transmission include:
• In most cases, zidovudine for prevention of maternal-fetal HIV-1 transmission should be given in combination with other antiretroviral drugs.
• Prevention of HIV-1 transmission in women who have received zidovudine for a prolonged period before pregnancy has not been evaluated.
• Because the fetus is most susceptible to the potential teratogenic effects of drugs during the first 10 weeks of gestation and the risks of therapy with zidovudine during that period are not fully known, women in the first trimester of pregnancy who do not require immediate initiation of antiretroviral therapy for their own health may consider delaying use; this indication is based on use after 14 weeks' gestation.
âš Boxed warning (FDA's strongest warning)
WARNING: RISK OF HEMATOLOGICAL TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS
Zidovudine tablets have been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease
.
Prolonged use of zidovudine has been associated with symptomatic myopathy
.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur
.
Zidovudine dosage
Oral Dosing
The recommended oral dose of zidovudine is 300 mg twice daily in combination with other antiretroviral agents.
Healthcare professionals should pay special attention to accurate calculation of the dose of zidovudine, transcription of the medication order, dispensing information, and dosing instructions to minimize risk for medication dosing errors.
Prescribers should calculate the appropriate dose of zidovudine for each child based on body weight (kg) and should not exceed the recommended adult dose.
Before prescribing zidovudine tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow a zidovudine tablet, the zidovudine syrup formulation should be prescribed.
The recommended oral dosage in pediatric patients aged 4 weeks to less than 18 years and weighing greater than or equal to 4 kg is provided in Table 1. Zidovudine Syrup should be used to provide accurate dosage when tablets are not appropriate.
Table 1. Recommended Pediatric Oral Dosage of Zidovudine
Body Weight (kg) | Total Daily Dose | Dosage Regimen and Dose
Twice Daily | Three Times Daily
4 to <9 | 24 mg/kg/day | 12 mg/kg | 8 mg/kg
≥9 to <30 | 18 mg/kg/day | 9 mg/kg | 6 mg/kg
≥30 | 600 mg/day | 300 mg | 200 mg
Alternatively, dosing for zidovudine can be based on body surface area (BSA) for each child. The recommended oral dose of zidovudine is 480 mg per m
2per day in divided doses (240 mg per m2 twice daily or 160 mg per m
2three times daily). In some cases the dose calculated by mg per kg will not be the same as that calculated by BSA.
The recommended dosage regimen for administration to pregnant women (greater than 14 weeks of pregnancy) and their neonates is:
Maternal Dosing
100 mg orally 5 times per day until the start of labor
.
During labor and delivery, intravenous zidovudine should be administered at 2 mg per kg (total body weight) over 1 hour followed by a continuous intravenous infusion of 1 mg per kg per hour (total body weight) until clamping of the umbilical cord.
Neonatal Dosing
Start neonatal dosing within 12 hours after birth and continue through 6 weeks of age. Neonates unable to receive oral dosing may be administered zidovudine intravenously. See Table 2 for dosing recommendations.
Table 2. Recommended Neonatal Dosages of Zidovudine
Route | Total Daily Dose | Dose and Dosage Regimen
Oral | 8 mg/kg/day | 2 mg/kg every 6 hours
Intravenous | 6 mg/kg/day | 1.5 mg/kg infused over 30 minutes, every 6 hours
Use an appropriate-sized syringe with 0.1-mL graduation to ensure accurate dosing of the syrup formulation in neonates. …
How to take Zidovudine — instructions & advice from the label
Hypersensitivity Reactions
Inform patients that potentially life-threatening hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) can occur while receiving zidovudine. Instruct patients to immediately contact their healthcare provider if they develop rash, as it may be a sign of a more serious reaction. Advise patients that it is very important that they remain under a healthcare provider's care during treatment with zidovudine
.
Neutropenia and Anemia
Inform patients that the major toxicities of zidovudine are neutropenia and/or anemia. The frequency and severity of these toxicities are greater in patients with more advanced disease and in those who initiate therapy later in the course of their infection. Advise patients that if toxicity develops, they may require transfusions or drug discontinuation. Advise patients of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced symptomatic HIV-1 disease
.
Myopathy
Inform patients that myopathy and myositis with pathological changes, similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine
. …
Warnings & precautions
Do not take this medicine if: Zidovudine tablets are contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to any of the components of the formulations.
Zidovudine should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells per mm
3or hemoglobin less than 9.5 g per dL. Hematologic toxicities appear to be related to pretreatment bone marrow reserve and to dose and duration of therapy. In patients with advanced symptomatic HIV-1 disease, anemia and neutropenia were the most significant adverse events observed. In patients who experience hematologic toxicity, a reduction in hemoglobin may occur as early as 2 to 4 weeks, and neutropenia usually occurs after 6 to 8 weeks. There have been reports of pancytopenia associated with the use of zidovudine, which was reversible in most instances after discontinuance of the drug. However, significant anemia, in many cases requiring dose adjustment, discontinuation of zidovudine, and/or blood transfusions, has occurred during treatment with zidovudine alone or in combination with other antiretrovirals.
Frequent blood counts are strongly recommended to detect severe anemia or neutropenia in patients with poor bone marrow reserve, particularly in patients with advanced HIV-1 disease who are treated with zidovudine. For HIV-1-infected individuals and patients with asymptomatic or early HIV-1 disease, periodic blood counts are recommended. If anemia or neutropenia develops, dosage interruption may be needed
.
Myopathy and myositis with pathological changes, similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine. …
Zidovudine side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
• Hematologic toxicity, including neutropenia and anemia
.
• Symptomatic myopathy
.
• Lactic acidosis and severe hepatomegaly with steatosis
.
• Hepatic decompensation in patients co-infected with HIV-1 and hepatitis C
.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The frequency and severity of adverse reactions associated with the use of zidovudine are greater in patients with more advanced infection at the time of initiation of therapy.
Table 3 summarizes adverse reactions reported at a statistically significant greater incidence for subjects receiving oral zidovudine in a monotherapy trial.
Table 3. Percentage (%) of Subjects with Adverse Reactions (Greater than or Equal to 5% Frequency) in Asymptomatic HIV-1 Infection (ACTG 019)
Adverse Reaction | Zidovudine 500 mg/day
(n = 453) | Placebo
(n = 428)
Body as a whole
Asthenia
Headache
Malaise
Gastrointestinal
Anorexia
Constipation
Nausea
Vomiting | 9%
a
63%
53%
20%
6%
a
51%
17% | 6%
53%
45%
11%
4%
30%
10%
aNot statistically significant versus placebo. …
Drug interactions
Stavudine
Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated
in vitro.
Nucleoside Analogues Affecting DNA Replication
Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the in vitro antiviral activity of zidovudine against HIV-1; concomitant use of such drugs should be avoided.
Concomitant use of zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated
in vitro.
Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.
About this medicine
Zidovudine (formerly called azidothymidine [AZT]), a pyrimidine nucleoside analogue active against HIV-1. The chemical name of zidovudine is 3'- azido-3'-deoxythymidine; it has the following structural formula:
Zidovudine USP is a white to beige, odorless, crystalline solid with a molecular weight of 267.24 and a solubility of 20.1 mg per mL in water at 25°C. The molecular formula is C
10H
13N
5O
4.
Zidovudine tablets, USP are for oral administration. Each film-coated tablet contains 300 mg of zidovudine USP and the inactive ingredients microcrystalline cellulose, sodium starch glycolate, magnesium stearate and opadry white. (hypromellose, polyethylene glycol, and titanium dioxide).
How it works: Zidovudine is an antiretroviral agent . Absorption and Bioavailability In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours. The AUC was equivalent when zidovudine was administered as zidovudine tablets or syrup compared with zidovudine capsules.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 437f55b2-f6d9-0065-e063-6294a90ab929. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin